The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...

AstraZeneca PLC ADR closed 14.68% short of its 52-week high of $87.68, which the company achieved on August 30th.

AstraZeneca PLC has announced significant changes to its board of directors. Karen Knudsen is proposed for election as a ...

ADB announced plans to provide at least $14 billion over 2022-2025 in a comprehensive program of support to ease a worsening food crisis in Asia and the Pacific, and improve long-term food security by ...

Malaria vaccination and HIV treatment are among numerous health programmes at risk in Uganda as the country's science research centres suffer the impact of a US freeze on overseas aid.

The Scientific Research and Experimental Development (SR&ED) tax incentives are intended to encourage businesses to conduct research and development in Canada. Corporations, individuals, trusts, and ...

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 ...

AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.

They are solving some of the current challenges in cybersecurity and imaging to protect people and organizations. Through research, RIT is making an impact. RIT is one of the top universities in the ...

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...